Olon S.p.A., an active pharmaceutical ingredients (API) contract development and manufacturing organization (CDMO) and generics supplier, has closed the acquisition of the manufacturing facility in Mahad, India.
                                                                 
Olon India will start definitively all the activities the next April 1st according to the strategy of Olon S.p.A.
 
“With this acquisition Olon achieved another successful milestone toward our growing strategy,” said Paolo Tubertini, chief executive officer, Olon.
 
Olon acquired Ricerca Biosciences’ chemical division in mid-2017 and Capua BioServices S.p.A., a global provider of CDMO services in the field microbial fermentation, in January 2019. With this acquisition, the company says it has finalized its three years development plan, and will move to its next target: to play an important role in the manufacturing of biologics API’s.
 
After the carve out from Sandoz, as part of the asset purchase agreement, the parties have committed to sign a long-term supply contract to guarantee continuous supply of Sandoz products manufactured in Mahad. The plant’s main product is Rifampicin—used to treat several types of bacterial infections, including tuberculosis—and its derivate.
 
Olon intends to invest in the site and pursue business development opportunities to optimize the plant’s utilization and expand its customer base.
 
The new company Olon API India Pvt Ltd. has invested in establishing a new head office in Mumbai, hiring additional people, improving the organization and its Indian market presence as well as beginning a technology transfer introducing new production to the Mahad site.
 
The Mahad site, which supplies products to Sandoz, a division of the Novartis Group,is an established and reputable API manufacturing facility in India with a reaction capacity of 580 m3 and approximately 270 employees.